At Dicerna, we create medicines that selectively silence the genes that cause disease using RNA interference, or RNAi. We are leaders in RNAi, harnessing the potential of this powerful and complex process to create medicines that can enhance the health and extend the lives of patients with rare diseases and common diseases with a genetic component.
Genes play a primary role in thousands of diseases. At Dicerna, we use our proprietary GalXC™ platform to develop safe and potent RNAi therapies that target and suppress genes. We are advancing our growing pipeline of product candidates designed to inhibit the genetic causes of diseases and disorders that affect the liver, kidney, cardiovascular system and central nervous system.
Dicerna brings together talented experts in biology, chemistry, clinical science, medicine and commercial development. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge, experience and sense of urgency needed to realize the full potential of RNAi technology and expedite the development of breakthrough therapies.
Offices:
Lexington, Mass.
Cambridge, Mass.
Xổ số miền nam và miền bắcBoulder, Colo.
2006
Founded
2014
Listed on NASDAQ
DRNA
Xổ số miền nam và miền bắcTrading Symbol
225+
Employees
As part of our commitment, Dicerna supports programs and activities that foster excellence in patient care and provide valuable scientific, medical and educational information to the medical and scientific communities as well as patient advocacy organizations. Learn more hereXổ số miền nam và miền bắc about Dicerna’s Industry Support program.
Xổ số miền nam và miền bắcWe use RNA interference, or RNAi, to create medicines that silence the genes that cause disease. Our goal is to provide life-changing therapies to people living with rare diseases and common diseases that have a genetic component.